|
|
Article: Cobalis Announces Delay in Reporting of Phase III Trial Results for PreHistin(TM) in Seasonal Allergic Rhinitis.
- Article from:
- Business Wire
- Article date:
- May 31, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IRVINE, Calif. -- Cobalis Corp. (OTCBB:CLSC), a pharmaceutical development company specializing in anti-allergy medications, today announced that it is concerned about apparent inconsistencies in the databases of the Phase III clinical trials for its drug PreHistin[TM]. Accordingly, it will delay release of the trial results until an audit of the trial data and procedures is completed.
The Company said its concerns included the possibility of incorrect data entry in patient-symptom diaries. Given inconsistencies it has identified, the Company does not know at this time which data are correct, and it said it must review source documents and conduct other quality ...